PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsHydroxyurea
Hydrea, Xromi(hydroxyurea)
Hydrea, Hydroxyurea, Siklos, Xromi (hydroxyurea) is a small molecule pharmaceutical. Hydroxyurea was first approved as Hydrea on 1982-01-01. It is used to treat BCR-ABL positive chronic myelogenous leukemia, brain neoplasms, essential thrombocythemia, head and neck neoplasms, and hypereosinophilic syndrome amongst others in the USA. The pharmaceutical is active against ribonucleoside-diphosphate reductase subunit M2 and ribonucleoside-diphosphate reductase large subunit.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
respiratory tract diseasesD012140
nervous system diseasesD009422
urogenital diseasesD000091642
hemic and lymphatic diseasesD006425
skin and connective tissue diseasesD017437
endocrine system diseasesD004700
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Droxia, Hydroxyurea, Xromi (discontinued: Droxia, Hydroxyurea)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Hydroxyurea
Tradename
Company
Number
Date
Products
HYDREACHEPLAPHARM ArzneimittelN-016295 RX1982-01-01
1 products, RLD, RS
XROMINova LaboratoriesN-216593 RX2024-04-04
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
droxiaNew Drug Application2025-09-12
hydreaNew Drug Application2025-09-15
hydroxyureaANDA2025-09-11
siklosNew Drug Application2025-02-05
xromiNew Drug Application2025-08-20
Agency Specific
FDA
EMA
Expiration
Code
HYDROXYUREA, SIKLOS, ADDMEDICA SAS
2024-12-21ODE-177
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01X: Other antineoplastic agents in atc
— L01XX: Other antineoplastic agents in atc
— L01XX05: Hydroxycarbamide
HCPCS
Code
Description
S0176
Hydroxyurea, oral, 500 mg
Clinical
Clinical Trials
396 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Sickle cell anemiaD000755EFO_0000697D57244521958144
Polycythemia veraD011087—D45110111629
ThalassemiaD013789EFO_1001996D5631352725
ThrombocytosisD013922—D75.8331081323
Essential thrombocythemiaD013920—D47.32991322
Hiv infectionsD015658EFO_0000764B204811518
Beta-thalassemiaD017086Orphanet_848D56.131251317
Hemoglobin sc diseaseD006450EFO_1001797D57.214—149
StrokeD020521EFO_0000712I63.9—23139
Vaso-occlusive crisesD000098644———231—5
Show 1 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938—C9571613—535
AnemiaD000740EFO_0004272D64.95128—931
Myeloid leukemiaD007951—C926129—426
Myeloid leukemia acuteD015470—C92.09135—425
PolycythemiaD011086EFO_0005804D75.11911—425
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340—278—217
NeoplasmsD009369—C80763—216
Primary myelofibrosisD055728—D47.4356—113
Myeloproliferative disordersD009196—D47.1262—312
Hematologic diseasesD006402EFO_0005803D75.9326—111
Show 36 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223—C85.91120——124
Large b-cell lymphoma diffuseD016403—C83.3812———15
B-cell lymphomaD016393——611———13
Non-hodgkin lymphomaD008228—C85.958——112
Head and neck neoplasmsD006258——311———12
Precursor cell lymphoblastic leukemia-lymphomaD054198—C91.027——19
Squamous cell carcinoma of head and neckD000077195——45———8
Burkitt lymphomaD002051—C83.726———7
MeningiomaD008579EFO_0003098D32.9—7———7
Hodgkin diseaseD006689—C8144———6
Show 105 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_0000544—1———34
Acquired immunodeficiency syndromeD000163EFO_0000765B201———34
Communicable diseasesD003141——1———23
Non-small-cell lung carcinomaD002289——3————3
Lung neoplasmsD008175—C34.903————3
Breast neoplasmsD001943EFO_0003869C502————2
Salivary gland neoplasmsD012468EFO_0003826D112————2
Verrucous carcinomaD018289——2————2
Pancreatic ductal carcinomaD021441——2————2
GliomaD005910EFO_0000520—2————2
Show 24 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Acute diseaseD000208——————11
Iron deficienciesD000090463—E61.1————11
Ischemic strokeD000083242——————11
Cerebral infarctionD002544—I63————11
ThrombosisD013927——————11
DiseaseD004194EFO_0000408R69————11
Bone marrow neoplasmsD019046——————11
Only childD009863——————11
Yin deficiencyD016710——————11
CardiomyopathiesD009202EFO_0000318I42————11
Show 9 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameHydroxyurea
INNhydroxycarbamide
Description
Hydroxyurea is a member of the class of ureas that is urea in which one of the hydrogens is replaced by a hydroxy group. An antineoplastic used in the treatment of chronic myeloid leukaemia as well as for sickle-cell disease. It has a role as a DNA synthesis inhibitor, an EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor, an antineoplastic agent, a genotoxin, an antimetabolite, a teratogenic agent, a radical scavenger, an immunomodulator and an antimitotic. It is a member of ureas and a one-carbon compound.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
NC(=O)NO
Identifiers
PDB—
CAS-ID127-07-1
RxCUI—
ChEMBL IDCHEMBL467
ChEBI ID44423
PubChem CID3657
DrugBankDB01005
UNII IDX6Q56QN5QC (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Hydroxyurea
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 32,384 documents
View more details
Safety
Black-box Warning
Black-box warning for: Droxia, Siklos, Xromi
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
8,036 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use